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 A Summary 
Summary 
Heme is a widely known cofactor molecule in many enzymes like hemoglobin, 
cytochromes and myoglobins. It is attached to these proteins covalently and classifies them 
as hemoproteins. In the last decade a growing number of reports on the regulatory role of 
heme in various molecular and cellular processes uncovered the signaling role of heme. 
Here, heme binds transiently or with low affinity to variety of proteins and regulates their 
function. Inspite of the number of reports on its regulatory role, they are poorly defined at 
structural level. Heme binds to these proteins through special amino acids called heme 
regulatory motifs (HRMs) such as cysteine-proline (CP), histidine and tyrosine. Studies 
conducted on CBS and the IL-36 cytokine family members during this project validated the 
heme-peptide knowledge at protein level. 
Cystathionine β-synthase (CBS) is a key enzyme in the sulfur metabolism and 
responsible for first step of the transulfuration pathway. Dysregulation of this enzyme 
causes homocystinuria which leads to serious pathological conditions like neural tube 
defects, osteoporosis, Alzheimer’s disease. CBS has a canonical heme binding site where 
heme binds as a cofactor along with pyridoxal-5-phosphate (PLP) and S-adenosyl-L-
methionine (Adomet) and is responsible for enzyme activity. The intrinsically disordered 
N-terminus, a 40 amino acids peptide segment of CBS, contains a CP motif along with 
histidine in its vicinity which binds to heme transiently. This N-terminal segment was fused 
with the streptococcal protein GB1 to produce a stable CBS protein for studies. NMR along 
with other biophysical studies conducted on this peptide segment unravels for the first time 
a second heme binding site where heme binds transiently to C 15P16 /H22 in a 
hexacoordinated manner and suggests a conformational change upon heme binding. 
Enzymatic assays done on this protein along with its mutants suggest heme binding to the 
N-terminal peptide segment is responsible for approximately 30% of the CBS protein 
activity. In addition, the data also suggests the advantages of employing the fusion protein 
GB1 in heme binding studies. 
During the study of this N-terminal CBS peptide, which is an intrinsically disordered 
protein (IDPs), a new NMR pulse sequence was developed to map the heme-IDP 
interaction. This new HCBCACON NMR experiment was as helpful as the classical [1H,15N]-
HSQC experiment because it allows to detect the effect of heme on side chains of a protein 
whilethe latter detects the effect of heme on the protein backbone. The HCBCACON 
experiment imparts the information either detecting 13CO, called carbon detection or 
detecting 1H, called proton detection. Apart from detecting a range of transient 
interactions, this experiment can be done at physiological temperature (37 °C) and in 
addition delivers proline residues information which is especially crucial when studying 
heme interactions with a CP motif.  
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IL-36α is another protein used to show the translation of heme-peptide study 
knowledge to the protein level. IL-36α is a proinflammatory cytokine which control the 
expression of other cytokines (IL-6, IL-8), chemokines and antibacterial peptides. Recently 
it has been characterized to be involved in psoriasis, rheumatoid arthritis and with latest 
intervention during pregnancy. Detailed analysis using various biophysical methods 
suggested the existence of two heme-binding sites located on it while analysis on the atomic 
level performed using NMR spectroscopy revealed the structural details. NMR studies 
performed on full length and truncated IL-36α shows no major structural changes upon N-
terminal pro-peptide truncation and that the heme binds at two sites in a penta-
coordinated fashion. In addition, the NMR results also explains the reason for the necessity 
of N-terminal processing for a full activation at structural level. Biological tests performed 
on IL-36α along with other two member of this cytokine family, IL-36β and IL-36γ, on 
fibroblast-like synoviocyte (FLS) cells from rheumatoid arthritis (RA) patients showed the 
heme binding to these proteins hindered the regulation of IL-36 mediated signaling. These 
biological studies on IL-36β and IL-36γ along with surface plasmon resonance (SPR) data 
prompted us to further investigate the different heme-binding motifs involved in the IL-36 
cytokine family. The initial solution NMR structure of IL-36 was determined to gain insight 
at structural level while site-directed mutagenesis studies coupled with spectroscopic 
techniques were employed to uncover the involved HRMs. The sequence similarity of IL-
36β with IL-36γ and the pre-established X-ray structure of IL-36γ helped us to unravel the 
possible HRMs involved in IL-36γ protein. Overall, all three members of the IL-36 family 
display a typical β-trefoil fold and suggest two heme-binding sites or heme-regulatory 
motifs on each molecule. In vitro studies performed on IL-36β and IL-36γ reveal the 
involvement of new amino acids in heme-binding beside the canonical HRMs. These newly 
identified amino acids add new information to the growing class of HRMs and also add 
novel aspects in determination of yet unidentified transiently heme-regulated proteins.  
 
 
 
 
 
 
 C Zusammenfassung 
Zusammenfassung 
Häm ist ein bekannter Kofaktor in vielen enzymatischen Verbindungen wie z.B. 
Hämoglobin, Cytochrome und Myoglobine. Die kovalente Verknüpfung des Häms 
klassifiziert die Proteine dabei als Hämoproteine. In der letzten Dekade zeigten Studien, 
dass Häm bedeutende regulatorische Rollen in zellulären Funktionen und molekularen 
Signalisierungsprozessen zukommt. Hierbei bindet Häm an seine Zielproteine oft nur in 
transienter Form oder mit geringer Affinität und beeinflusst damit deren Funktion. Trotz 
der steigenden Anzahl von Berichten über die regulatorischen Eigenschaften von Häm, 
liegen die strukturellen Grundlagen dieser Abläufe noch im Dunkeln. Häm bindet an seine 
Zielproteine mittels spezieller Aminosäuren oder Aminosäuresequenzen, sogenannten 
Häm-regulatorischen Motiven (HRM), wie z.B. Cystein-Prolin (CP), Histidine und Tyrosin. 
Im Rahmen dieses Projektes konnten dazu Erkenntnisse, die im Vorfeld an Häm-Peptid-
Komplexen gewonnen wurden, durch Studien an Cystathionine- -Synthase und Proteinen 
der Interleukin-36 Zytokinfamilie auf Proteinebene validiert werden. 
Cystathionine-β-synthase (CBS) stellt ein Schlüsselenzym im Schwefel-Metabolismus 
dar und ist für den ersten Schritt des Transsulfurationsmechanismus verantwortlich. 
Fehlregulation dieses Enzyms führen zu Homocystinurie, die mit schweren 
Krankheitsverläufen, wie neuronalen Tubendefekten, Osteoporose, Alzheimer, verbunden 
ist. CBS besitzt eine Bindungsregion in der Häm als Kofaktorzusammen mit Pyridoxal-5-
phosphat (PLP) and S-adenosyl-L-Methionin (Adomet) bindet und für die Enzymfunktion 
verantwortlich ist. Der intrinsisch-ungeordnete N-terminale Bereich von CBS, bestehend 
aus 40 Aminosäuren, beinhaltet ein CP-Motiv und Histidine in dessen Umgebung. Dieses 
N-terminale Segment wurde zu Studienzwecken mit dem Streptokokken-Protein GB1 
fusioniert. NMR-Spektroskopie zusammen mit anderen biophysikalischen Studien an 
diesem Segment zeigte erstmals, dass Häm transient an C15P16 /H22 in einer 
hexakoordinierten Form bindet und damit eine konformationelle Änderung hervorruft. 
Mittels enzymatischer Assays an diesem Protein und seinen Mutanten konnte zudem 
nachgewiesen werden, dass dieses N-terminale Segment für ca. 30% der Proteinaktivität 
von CBS verantwortlich ist. Zusätzlich konnte gezeigt werden, dass der GB1-Fusionsprotein-
Ansatz Vorteile bei der Untersuchung der Häm-Bindung an intrinsisch-ungeordnete 
Peptide (IDP) aufweist. Während der Untersuchungen an diesem N-terminalen CBS-Peptid 
konnte damit eine neue NMR-Pulssequenz zur Kartierung der Häm-IDP-Wechselwirkung 
etabliert werden. Dieses neue HCBCACON NMR-Experiment erweist sich ähnlich 
vorteilhaft wie ein klassisches [1H,15N]-HSQC-Experiment. Jedoch erlaubt es, statt wie im 
letzteren nur Proteinrückgratinformationen, die evtl. noch durch chemischen Austausch 
nachteilig maskiert sind, direkt Informationen von interagierenden nicht-austauschenden 
Seitenkettenatomen zu detektieren. Das HCBCACON-Experiment erlaubt dabei, 
Informationen entweder über 13CO-Detektion oder, in einer anderen Variante, über 1Hα-
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Detektion zu erlangen und führt auch bei physiologischen Temperaturen (37 °C) zu 
auswertbaren Spektren. Nicht zuletzt liefert das Experiment Daten über Prolin-Reste, was 
besonders bei Studien von CP-Motiven von Vorteil ist. 
IL-36α ist ein weiteres Untersuchungsobjekt, das aus Translation der Erkenntnisse von 
Häm-Peptid-Studien auf die Proteinebene hervorging. IL-36α stellt ein 
proinflammatorisches Zytokin dar, das die Expression anderer Zytokine (z.B. IL-6, IL-8), 
Chemokine und antibakterieller Peptide kontrolliert. In jüngerer Zeit wurde nachgewiesen, 
dass es mit Krankheitbildern wie Psoriasis und Rheumatoider Arthritis assoziiert ist und 
auch in der Immunantwort bei Schwangerschaftsprozessen eine Rolle spielt. Die Analyse 
mittels verschiedener biophysikalischer Methoden deutete auf die Existenz von zwei 
Hämbindungsstellen in IL-36α hin, deren strukturelle Details per NMR-Spektroskopie auf 
atomarer Ebener definiert werden konnten. Mittels NMR-Studien konnte gezeigt werden, 
dass das Volllängenprotein und seine N-terminal verkürzte biologisch aktive Form keine 
strukturellen Änderungen aufweist. Es konnte auch gezeigt werden, dass die Propeptid-
Prozessierung unumgänglich ist, um die strukturellen Voraussetzungen für die Bildung 
eines aktiven Komplexes zu erreichen. In Bezug auf die Hämbindung wurde deutlich, dass 
diese an zwei Bindungstellen in Pentakoordination erfolgt. Biologische Tests mit IL-36α 
und den weiteren zwei Mitgliedern dieser Zytokin-Familie, IL-36β and IL-36γ, an 
Fibroblast-artigen Synoviocyten-Zellen von Patienten mit rheumatoider Arthritis zeigten, 
dass Hämbindung die Regulierung der IL-36-bedingten Signalkaskade beeinflusst. Diese 
und Oberflächen-Plasmon-Resonanz-Daten von IL-36β and IL-36γ stimulierten die 
Ausweitung unsere Untersuchungen auf andere Häm-Bindungsmotive in der IL-36-
Zytokinfamilie. Die Bestimmung der initialen NMR-Lösungsstruktur von IL-36β erlaubte 
Einblicke auf struktureller Ebene, während via Mutagenese und spektroskopischer 
Untersuchungen die beteiligten HRM bestimmt werden konnten.Die 
Sequenzähnlichkeiten von IL-36β mit IL-36γ und die bekannte Röntgenstruktur von IL-36γ 
unterstützten dabei die Nutzung des Mutagenese/NMR-Ansatzes zur Aufdeckung der HRM 
in IL-36γ. Im Ergebnis weisen alle drei Mitglieder der IL-36-Familie eine typische β-Trefoil-
Faltung mit zwei Hämbindungsstellen auf. Während in IL-36α ein CP-Motiv an der 
Hämbindung beteiligt ist, bindet Häm bei IL-36β und IL-36γ mittels nicht-kanonischer 
Wechselwirkungen. Die dabei neu identifizierten Häm-bindenden Aminosäuren erweitern 
die Klasse der Häm-regulatorischen Motive und eröffnen neue Perspektiven für die 
Aufdeckung weiterer transient hämbindender Proteine mit bioregulatorischen Funktionen. 
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1 Introduction 
1.1 Heme 
Heme (iron protoporphyrin IX) is a ubiquitous molecule present in aerobic and 
anerobic life from primitive prokaryotes to complex eukaryotes [1]–[3]. The term heme is 
derived from Greek haima, meaning blood. It is an organic molecule with complex structure 
containing four pyrrole rings, connected to a central iron atom. The four modified and 
connected pyrrole rings (tetrapyrrole structure) are also called porphyrin. Ultimately with 
the addition of iron, the system is named iron protoporphyrin-IX or heme. Usually heme is 
the generic term for both, the ferrous (Fe2+) and the ferric (Fe3+) form of iron in 
protoporphyrin-IX. However, strictly applied, ferrous protoporphyrin-IX refers to heme and 
ferric protoporphyrin-IX is represented by the term hemin. In the following studies we have 
used hemin but refer to it as heme [4]. Different types of heme exist in nature, e.g. heme A, 
heme B, heme C, heme O. They all are derivatives of each other with a basic porphyrin ring 
and differ by variations in the sidechains. The most abundant heme present in nature is 
heme B, and it is involved in many biological activities. The protoporphyrin-IX of heme B 
consist of four methyl groups, two vinyl groups, and two propionate side chains as well as 
an iron atom covalently connected to four nitrogen atoms of the respective pyrrole rings 
(Figure 1). This arrangement is leaving the heme iron with two free axial coordination sites 
for potential ligand interactions, e.g. proteins and small gas molecules (NO, CO, O2) (Fig. 
1).   
 
Figure 1: Structure of heme B and two co-ordination sites (arrow) shown for interaction (adapted from [4]) 
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1.2 Heme homeostasis 
1.2.1 Heme biosynthesis and transport 
Cellular homeostasis of heme is governed by iron and heme transport. The toxic nature 
of free heme required evolution of stringent regulation in biosynthesis and degradation in 
all the aerobic and anaerobic life with well-developed pathways. Liver and bone marrow are 
the two major heme production factories in the human body. Liver produces 15% of heme, 
while the bone marrow makes 80% of heme in a human body [4], [5]. The heme biosynthesis 
pathway in mammals involves eight enzymes where three of them are present in 
mitochondria, while the other five are acting in the cytoplasm. This pathway can be divided 
in four process steps starting with formation of the pyrrole ring, converting to tetrapyrrole 
ring, followed by modification in side chain of the tetrapyrrole ring to form protoporphyrin 
IX, and ultimately the incorporation of iron ion (Figure 2).                     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Biosynthesis of heme (adapted from [6] 
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The first step of heme biosynthesis starts in mitochondria of erythrocytes where the 
pyrrole formation begins with the substrates succinyl coenzyme A and glycine in presence 
of aminolevulinic acid synthase (ALAS), the first rate-limiting enzyme in the pathway to 
form 5-aminolevulinic acid as precursor for pyrrole ring formation. ALAS has two isozyme 
proteins, ALAS1 and ALAS2. ALAS1, also known as hepatic ALAS (ALAS-H), is ubiquitously 
expressed in all tissues, while the ALAS2 or ALAS-E are specifically expressed in 
erythrocytes cells and are located on chromosomes 3p21.1, Xp11.21, respectively. Both 
isozymes are regulated by heme. However, only ALAS1 expression and degradation is 
regulated by feedback mechanism of heme iron, while ALAS2 expression remains 
unaffected by heme. This negative feedback mechanism of heme is one of the processes for 
intracellular heme homeostasis in all cells except for red blood cells (RBCs). 
The transportation of synthesized ALA in to the cytosol is currently not fully 
understood. In 2013, Bayeva et al. showed that knockdown of ABCB10 (inner mitochondrial 
membrane) in cardiac myoblasts resulted in reduced heme levels and suggests that ABCB10 
might be involved in export of ALA in the cytoplasm. However, other studies in yeast on 
the glycine transporter Hem25 knockdown showed a decreased level of glycine and, thus, 
ALA. Sequence homology of Hem25 (approx. 30% amino acid similarity) suggests a 
similarity with the SLC25A38 gene in Homo sapiens and slc25a38a, slc25a38b in Danio rerio 
[7], which is further strengthened by two other studies [8], [9]. After reaching the cytosol 
two molecules of ALA condense to form monopyrrole porphobilinogen, catalyzed by 
aminolevulinate dehydratase (ALAD) [10]. 
The second step is the formation of uroporphyrinogen III. Starting with polymerization 
of four PBG molecules in presence of porphobilinogen deaminase (PBGD), an initial 
unstable tetrapyrrole, hydroxymethylbilane (HMB) is formed. HMB is further converted to 
uroporphyrinogen III by the enzyme uroporphyrinogen III synthase (URO3S) [10]. 
In the third step, modification of side chains (acetate and propionate chains) occurs in 
uroporphyrinogen III to form coproporphyrinogen III (CPG III) involving the 
uroporphyrinogen carboxylase enzyme. This phase is followed by CPG III conversion to 
protoporphyrinogen IX during localization inside the mitochondria mediated by a 
peripheral- type benzodiazepine receptor [11], [12] using coproporphyrinogen oxidase 
enzyme (CPO) located in the mitochondrial intermembrane space [10]. After import into 
the mitochondria, oxidation of protoporphyrinogen IX is catalyzed by the enzyme 
protoporphyrinogen oxidase (PPO) to form protoporphyrin IX (PPIX). 
The final step is the incorporation of iron (Fe2+) into protoporphyrin IX inside the inner 
mitochondrial membrane by an enzyme ferrochelatase (FECH) [10]. FECH is produced 
inside the cytosol with a leader peptide targeted to mitochondria. Subsequently, cleaving 
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the leader peptide produces mature FECH [13]. FECH is the second rate-limiting enzyme 
after ALAS in the heme biosynthesis pathway. The FECH expression level is intracellularly 
controlled by iron concentration through the iron-sulfur cluster located on the C-terminus 
[14]. Iron localization inside the mitochondria is governed by the transport protein 
transferrin, to which 95% of iron (Fe3+) in plasma is bound. Subsequently, it delivers a major 
part to erythroid progenitor cells by binding to its transferrin receptor 1 (TFR 1) located on 
the bone marrow to form new RBCs. An estimated 80% of TFR 1 is present on the erythroid 
marrow of the human [15]. Per day, our body utilizes 25 mg of iron to form 200 billion new 
RBCs [16]. The iron (Fe3+)-transferrin complex is internalized through endocytosis and 
acidified to separate iron from transferrin. STEAP3 (six-transmembrane epithelial antigen 
of the prostate 3) reduces the Fe3+ to Fe2+ for the transport in the cytosol through the DMT 
1 transporter [17], [18]. 
The final step is the transport of reduced iron (Fe2+) from the cytosol in to the inner 
mitochondria. First, iron crosses the outer mitochondrial membrane through unknown 
mechanism. However, a recent study suggests iron could bind to low molecular weight 
ligands in the cytosol and freely diffuse into semi-permeable outer mitochondrial 
membrane [16]. Second, iron crosses the inner mitochondrial membrane through two 
known iron transporters, mitoferrin 1 (on erythroid cells, non-erythroid cells)[19] and 
mitoferrin 2 (on non-erythroid cells),  located in the inner mitochondrial membrane, to 
finally reach the destination enzyme FECH where iron is inserted into the PPIX [20]. To 
facilitate the efficacy of iron insertion in PPIX, mitoferrin 1 forms the complex with FECH 
and ABCB10 proteins [21], [22] and ultimately forms iron-PPIX (heme). ABCB10 increases 
the stability of mitoferrin 1 and thus increases the iron transport into the mitochondria [23].  
Synthesized heme can be exported out of the cell through the recently identified heme 
receptor/transporter system of Feline Leukemia virus subgroup C (FLvcr1). There are two 
isoforms of FLvcr1 present in mitochondria FLvcr1a and FLvcr1b, located on plasma 
membrane and mitochondrial membrane, respectively [24]. In vitro and in vivo studies 
supported the role of FLvcr1b in heme export, where suppression of FLvcr1b leads to 
mitochondrial heme accumulation and termination of erythroid differentiation, while 
overexpression leads to intracellular heme accumulation and erythroid differentiation [24], 
[25]. Multiple studies suggest their role in heme homeostasis but further research has to be 
done to uncover the role of these transporters. 
1.2.2 Heme catabolism and iron recycling 
Hemoglobin is the major source of heme, found in RBCs. Accumulation of heme in 
senescent RBCs and other sources is cytotoxic and must be cleared from cell. The average 
life of RBCs is around 120 days and after that it undergoes degradation in macrophages of 
liver, spleen and bone marrow, collectively called the “reticuloendothelial system” (RES) 
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[26]. This RES is tightly regulated in mammals and constitutes not only for heme 
degradation but also for biosynthesis by recycling iron. Our body daily recycles 25 mg of 
iron through the RES from RBCs and almost all of it returns back to the bone marrow for 
erythropoiesis to make a new batch of RBCs. Only 1-2 mg of iron is absorbed each day 
through enterocytes in the intestine in form of heme or non heme iron [16]. Heme 
homeostasis is regulated by two systems: 1) Scavenger proteins present in plasma like e.g. 
hemopexin bind excess free heme and transport it to macrophages of the RES [27], [28]. 2) 
Intracellular enzymatic degradation of heme through heme oxygenases (HMOXs), the most 
important enzymes responsible for the metabolism of heme, is located in the endoplasmic 
reticulum of the RES (Figure 3).  
 
Figure 3: Schematic representation of heme degradation by HMOX enzymes 
During hemolysis, free heme and hemoglobin leak into the blood circulatory system 
and are immediately bound to scavenger proteins like hemopexin and haptoglobin, 
respectively, with moderate affinity before being transferred to RES. In addition, as RBCs 
complete their fate, they also travel ultimately to macrophages of RES. Here, RBCs are 
internalized in macrophages by phagosomes, while the heme-hemopexin or hemoglobin-
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haptoglobin complex is imported via the scavenger receptors LRP (or CD91) and CD163, 
respectively [29]–[33]. The RBC phagosome fuses with the lysosome and forms the 
phagolysosome, this process called as erythrophagocytosis. The phagolysosome contains 
hydrolytic enzymes, which degrade the hemoglobin in RBC to globin and release the heme 
[16]. This liberated heme undergoes the same fate as other internalized heme moieties. All 
the heme is exported out to the cytosol through the HRG1 transporter located on the 
lysosome/ endosome membrane and this HRG1 has been seen upregulated during 
erythrophagocytosis on the phagolysosome/endosome membrane [34]. It has been 
suggested that some portion of the heme is catabolized inside the phagolysosomes and 
released iron exported in cytosol through DMT1 homologue (NRAMP1) located on the 
phagolysosome membrane [35]–[37]. Heme export in the cytosol induces expression of 
HMOXs enzymes located on endoplasmic reticulum [38]. Higher expression of HMOXs 
enzymes makes macrophages more resistant to heme toxicity than endothelial cells [39]. 
This enzyme has two isoforms, HMOX1 and HMOX2, which perform the same function to 
break the heme into the first-order degradation products iron (Fe2+), CO and biliverdin IX 
(Fig. 3). HMOX1 is an inducible enzyme present ubiquitously in almost all cells and tissues. 
It is highly upregulated upon heme exposure or other oxidative stress conditions and 
prevents the oxidative stress in cells [40]. Expression of HMOX1 is directly linked to another 
enzyme, namely ferritin (iron sequestering protein), which is upregulated in parallel with 
HMOX1 and neutralizes the pro-oxidant effect of iron by binding to it [41]. HMOX2 is a 
non-inducible isoform and majorly expressed in brain and testis and has been shown to 
protect against ischemic injuries [42], [43]. In 2005, Kemp [44] showed that HMOX2 serves 
as a potential oxygen sensor for a calcium-sensitive potassium (BK) channels. 
Enzymatic degradation of heme can be divided into a few important steps. First heme 
is degraded to hydrophilic biliverdin IX via HMOXs enzymes involving NADPH, O2 and 
cytochrome reductase to reduce the ferric iron from heme. This degradation also produces 
iron (Fe2+), which is stored in ferritin (used for erythropoiesis) and CO, recently recognized 
as a signaling molecule (Fig. 3) [45]. Biliverdin IX is further degraded to the second-order 
products, hydrophobic bilirubin via biliverdin reductase using NADPH and H+.  
For further degradation an export out of the cells into the blood takes place where 
bilirubin binds albumin and forms a bilirubin-albumin complex. This complex reaches the 
liver where UDP-glucuronyl transferase, using two UDP-glucuronic acid molecules, 
converts it to hydrophilic bilirubin diglucuronide (BDU). Either it is excreted through the 
kidney or it is further degraded in the intestine by gut bacteria to urobilinogen (UB), 
stercobilin (SB), and eventually excreted through urine and faces [46], [47]. In 2017 [48] it 
was shown that bilirubin, biliverdin, and bilirubin ditaurate promote the secondary 
structure formation in intrinsically disordered antibacterial peptides, and bilirubin also 
inhibited the heme regulated inhibitor protein (HRI) [49].  
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Bilirubin oxidation products (BOXes) are the third or end degradation products of 
bilirubin. As the name suggests, these are produced after the oxidation of bilirubin during 
subarachnoid hemorrhage (SAH) conditions. SAH is the bleeding in the subarachnoid space 
and characterized by free radical formation in cerebrospinal fluid, acting upon biliverdin, 
bilirubin, and heme to form BOXes. In 2002, Clark et al. [50] found BOXes in cerebrospinal 
fluid of subarachnoid hemorrhage patients with vasospasm while searching for vasoactive 
compounds. Later these isomers were classified as BOX A and BOX B [51]. Recently a new 
Z-BOX C was identified in human bile samples which has potential relevance for liver 
dysfunction and cerebral vasospasms [52]. These BOXes are vasoactive in nature as shown 
by in vitro and in vivo models of rat brain vessels [50], [53]. They are also involved in 
inhibition of human Slo1 BK channels and suggested to play a role in smooth muscle 
regulation [54]. Because of their light-sensitive nature and low abundance, they are not well 
explored, but a potential therapeutic potential is proposed [55]. 
1.3 Regulatory Role of Heme in Biological Processes 
Heme as a ubiquitous molecule in all aerobic life has been extensively studied as a 
prosthetic group, bound to hemoproteins. The most common roles are in oxygen binding 
with hemoglobin and myoglobin, in electron transport in the respiratory chain through 
cytochromes, or being a structural part of various proteins. In all those processes, heme is 
tightly bound to the proteins and called a cofactor or prosthetic group. But in the last 
decade heme has emerged out as a versatile signaling or regulatory molecule for many 
receptors, transcription factors and proteins (Table 1), thus regulating many biological 
processes ranging from cellular growth and survival to fundamental cellular processes like 
protein synthesis or localization [4].  Heme binds to these proteins through combinations 
of special amino acids sequences, called heme binding motifs (HBM) or heme regulatory 
motifs (HRM) such as the cysteine-proline (CP) motif. The term HRM was first used by 
Lathrop in 1993 [56], when they first identified a CP motif in the aminolevulinic acid 
synthase (ALAS) protein and found that heme can regulate the ALAS protein (details 
mentioned in section 1.3.1). CP is the most prominent motif known to date and binds 
directly to the central iron atom of heme. Over the last decades some other amino acid 
based motifs were identified which can directly bind to the heme iron like tyrosine and 
histidine. Heme as versatile molecule can also interact with other amino acids in proteins 
via its porphyrin ring or propionate side chains through electrostatic and hydrogen bonding 
[57], [58].  
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Table 1: Publications reporting transiently heme binding proteins  
‘?’ shows either contradictory publications or heme binds to protein but binding site not confirmed 
The identified heme-regulated proteins can be classified into two categories based upon 
their structural characteristics: 1) Intrinsically disordered proteins or unstructured proteins 
S.No. Protein Heme Binding 
Area 
HBM/HRM Predicted IDP 
content 
References 
1.  5-Aminolevulinate synthase 1 
(ALAS1) 
IDPRs CP  [56], [59] 
2.  Bach1 IDPRs CP 50 [60]–[62] 
3.  Heme oxygenase 2 
(HMOX2) 
Structured CP ? 25 [63] 
4.  Iron regulatory protein 2 
(IRP2) 
 CP, H 20 [64], [65] 
5.  Slo1 (BK) IDPR CxxCH 22 [66] 
6.  Potassium channel 
(Kv1.4) 
IDPR CxxHx18H 26 [67] 
7.  ATP-sensitive potassium 
channel (KATP) 
IDPR CxxHx16H  [68] 
8.  Rev-ErbA IDPR H 57 [69] 
9.  Circadian clock Period 2 
(PER2) 
IDPR CP ? 53 [70], [71] 
10.  Microprocessor complex 
subunit DGCR8 
IDPR C, W 48 [72] 
11.  Tumor suppressor P53 IDPR CP 49 [73] 
12.  α-Synuclein IDP ? 52 [74] 
13.  Amyloid beta peptide-40 
(Aβ-40) 
 H 44 [75]–[77] 
14.  Staniocalcinin1 Structured CS 27 [78] 
15.  Staniocalcinin2 Structured CP 37 [79] 
16.  Cystathionine-β-synthase 
(CBS) 
IDPR CP, H 32 [80] 
17.  Janus Kinase 2  
(JAK2) 
Structured CP ? 15 [81] 
18.  Src kinase Structured CP  ? 27 [82] 
19.  Interleukin-36α Structured CP, Y 11 our lab 
20.  Interleukin-36β Structured Q, N 14 our lab 
21.  Interleukin-36γ Structured Q, N 23 our lab 
 9 Introduction 
(IDPs) or Intrinsically disordered protein regions (IDPRs), which do not possess any 
secondary or tertiary structure; 2) Globular or structured proteins. Heme may bind 
moderately or interact transiently (in M range) with both classes of proteins and thus 
regulate their functions. 
1.3.1 Intrinsically disordered proteins/protein regions (IDPs/IDPRs) regulated by 
heme  
Identification of IDPs in the last two decades challenged our understanding of the 
structure-function paradigm of proteins. It was believed that function of a protein is always 
linked to their structure and that an active enzyme/protein always has a secondary and 
tertiary structure. This led to theories like the ‘lock and key’ model. A large and growing 
number of reports on IDPs opened a new, ‘unstructural’ biology concept, where these 
unstructured proteins are carrying out a large variety of biological functions. According to 
bioinformatics predictions, these disorders are very common and can be found across all 
species. However, their occurrence is significantly higher in eukaryotes than in prokaryotes 
and there exists a strong correlation with regulatory and signaling functions [83], [84]. 
Approximately 10-35% of prokaryotic proteins and 15-45% of eukaryotic proteins contain a 
significant number of these disordered regions with a minimum length of 30 amino acids. 
IDPs have less hydrophobic residues and are enriched in polar and charged residues [85], 
[86]. IDPs can form different conformations because of their considerable flexibility and 
can interact with a large variety of partners, which explains why they are highly abundant 
in important cellular processes like transcription or signaling [87]–[89]. As reported in 
literature IDPs/ IDPRs can undergo a disorder to order transition upon binding to their 
ligands (other proteins or small molecules) (Figure 4) [80], [90].  
 
Figure 4: Schematic representation of the free-energy landscapes of ordered and disordered proteins. Structured 
or ordered proteins (red) have a free-energy landscape with a well-defined global minimum 
conformation, which can bind small molecules with lower affinities (modified from [91]) 
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It is interesting to note that most of the identified transiently heme binding proteins 
either are complete IDPs or contain IDPRs in the protein sequence and that many heme 
binding processes take place in these disordered regions (Table 1). Here are few examples: 
ALAS, aminolevulinic acid synthase, as introduced earlier, is the first rate-limiting 
enzyme in heme biosynthesis and has two forms: ALAS1 and ALAS2. Only the ALAS1 
isoform displays a N-terminal disordered region (IDPR). ALAS1 is known to be negatively 
feedback regulated by heme and maintains intracellular heme levels. This negative feedback 
regulation is known at transcription, translation and localization of protein levels. Several 
studies have been done to find how heme destabilizes the ALAS1 mRNA.  It is known that 
heme destabilizes the ALAS1 mRNA, which leads to repressed translation of ALAS1 protein, 
but the exact mechanism is not fully understood (Figure 5) [92], [93].  The ALAS1 precursor 
protein contains three cysteine-proline (CP1, CP2 and CP3) motifs heme regulatory motifs 
(HRM) and two of them are located in N-terminal disordered leader peptide sequences, 
which is responsible for ALAS1 protein localization in mitochondria. While the CP3 motif 
is located on the N terminus of mature ALAS1 protein and this mature protein is formed 
after the proteolytic cleavage of leader sequence (removing CP1, CP2 motif).  Previously only 
CP1, CP2 were suggested to be involved in ALAS1 protein mitochondrial localization but 
recent studies showed the role of CP3 motif in maturation of ALAS1 protein in 
mitochondrial matrix [56], [94]. Maturation of ALAS1 proteins requires the proteolytic 
cleavage of leader peptide sequence in mitochondrial matrix. This proteolytic cleavage has 
been done by two ATP dependent proteases, Lon peptidase1 (LONP1) [95] and ClipX-like 
protein (ClpXp) [96], identified in mitochondrial matrix. Recently Kubota [97] suggested 
two theories for ALAS1 degradation mediating heme. The first one is that ClpXP identifies 
and modifies ALAS1 in the presence of heme and directly degrades ALAS1 protein. A second 
theory iss that LONP1 and ClpXP together mediate the ALAS1 protein degradation in the 
presence of heme, which was supported by Tian [98]. According to this theory, during 
increased intracellular heme concentration, heme binds to the CP3 motif of ALAS1 protein 
and induces oxidative modification of ALAS1. Modified ALAS1 protein is recognized by 
ClpXP protein and forms a complex with LONP1 protein triggering LONP1-mediated 
degradation of the ALAS1 protein. Their study suggests the possible role of both the 
proteases but the exact mechanism of heme-mediated degradation of ALAS1 is still not 
clear. CP motifs are conserved in different species of ALAS1 and ALAS2 but heme-mediated 
repression is only observed for ALAS1, suggesting a different mechanism of inhibition for 
ALAS2 in erythroid precursor cells. 
 11 Introduction 
 
Figure 5: Heme regulates ALAS1 at different levels (Negative feedback regulation) 
Similarly, Bach1, a transcriptional repressor which binds to the heme transiently, 
downregulates the expression of heme homeostasis regulating genes like HMOX1 and 
globin genes  [61], [99]. Interestingly, Bach1 is the first identified mammalian transcription 
factor that binds to heme in a disordered region of the protein (IDPRs) [60]. Bach1 is a big 
protein (739 amino acids) containing multiple domains. There are six CP motifs located on 
Bach1 at different regions but only 4 or 5 CP motifs might bind to heme (Figure 6) and 
govern its inhibition activity upon heme binding [60], [100]. Three of these CP motifs are 
located proximal to the bZip (basic leucine zipper) domain and act as a DNA-binding 
domain. It has been suggested CP3, CP4, CP5 and CP6 motifs bind to heme and are involved 
in DNA binding to genes containing Maf recognition elements like HMOX1 or globin genes 
[101]. At low heme concentration, Bach1 and small musculoaponeurotic fibrosarcoma 
proteins (Maf) form a heterodimeric complex. This Bach-Maf heterodimer binds to the Maf 
recognition element (MARE) present on the enhancer region of HMOX1 and on the globin 
gene and repress their expression. Upon increased heme concentration inside the cell, the 
Bach1-Maf complex is detached from MARE by activators (Nrf1,2,3) and dissociates. Nrf1,2,3 
activators bind small Maf proteins and form a complex which binds to the MARE region 
and express the genes (Figure 7). Only CP3 and CP4 are involved in the nuclear export of 
the Bach1 protein via the nuclear exporter Crm1 [102], [103]. In 2007 Zenke et al. showed that 
heme can regulate Bach1 degradation through a complex proteasome degradation 
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mechanism via the HOIL-1 ubiquitination protein in different cells and suggested that CP3, 
CP4, CP5 are involved in this process. (Figure 6). Interestingly, HOIL-1 also is involved in 
the degradation mechanism of another heme homeostasis protein, iron regulatory protein 
2 (IRP2). Heme also binds to this protein via the CP and H motif and promotes its 
degradation [64].  
Bach2 also binds to heme and regulates the differentiation of B-cells and T-cells [104]. 
Both isoforms are members of the basic leucine zipper (bZip) family of transcription factors 
and evolved to regulate sophisticated functions in higher eukaryotes [105].  
Recent studies also indicate the regulation of ion channels by reversible heme binding 
such as potassium channel Kv1.4 where its intracellular disordered part binds to heme and 
modulates the action potential across membrane in cells [67]. Heme also induces 
polyreactivity in immunoglobulins (IgG, IgM, IgE etc.)  which leads to a range of new 
antigen binding specificities [106]. In addition, in 2015 Gupta et al. demonstrated that heme 
induced reactivity of monoclonal IgG1 can neutralize the Japanese Encephalitis viruses. 
There are plenty of further examples where heme binds to IDPs/ IDPRs regions mostly with 
cysteine and histidine residues as shown in Table 2 across the different biological processes. 
 
Figure 6: A) Domain structure of human Bach1 protein showing six CP motif, B) Different CP motifs involved in 
heme mediated regulation of Bach1 protein 
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Figure 7: Diagrammatic representation showing Bach1 regulation in presence and absence of heme at 
transcriptional level 
1.3.2 Structured globular proteins regulated by heme 
Unlike IDPs, not many structured proteins that can transiently bind to heme and 
regulate their function are identified today. There are two structured non-receptor protein 
kinases known to bind heme that contain CP motifs at least. The most recent examples in 
this category are the interleukin-36 cytokine family members, which were identified in our 
lab (Publication 3, Publication 4, Further results). 
Src kinase is the first identified oncogene and one of the extensively studied kinases 
[107]–[109]. It is a member of the non-receptor tyrosine kinase family. Members of this 
family phosphorylate at tyrosine amino acids and play a critical role in downstream signal 
transduction pathways of many important processes like proliferation, cell division, 
adhesion, survival in normal and cancer cells [110]–[121]. Usually, Src is maintained in an 
inactive state and only activated transiently during normal cell events like cell division or 
induced during abnormal events like mutation or human cancers. This kinase contains two 
tyrosine residues (Tyr419 and Tyr530) and maintains its activity through phosphorylation 
at these sites. Phosphorylation at Tyr419 is responsible for full activation of Src, while 
phosphorylation at Tyr530 has an inhibitory effect, which leads to an inactive conformation 
[110], [122]. It has been shown that heme can enhance the phosphorylation at Tyr530 and 
eventually inactivate this enzyme, while showing no effects on Tyr419. This heme-induced 
immediate phosphorylation leads to the inactive conformation of this enzyme, which has 
been confirmed by a protease (trypsin) based digestion sensitivity assay [82]. Interestingly, 
it has 3 CP motifs, which constitute potential heme interaction sites. Two of these HRMs 
present proximal of its tyrosine phosphorylation sites (Figure 8). However, it is not fully 
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understood on which site heme binds and further studies need to be performed to identify 
the specific heme-binding site. 
 
Figure 8: Domain structure of Src kinase with CP motif location and possible heme interaction sites (adapted 
from[4]) 
Janus kinase 2 (JAK2) is another structured kinase, which was identified together with 
the Src kinase for heme mediated phosphorylation. It is also a non-receptor tyrosine kinase, 
member of the Janus kinase family and plays a pivotal role in signal transduction of various 
processes like cell growth, histone modification, erythropoiesis, development of a cell and 
cytokine receptors signaling (innate and adaptive immunity). Its central role in numerous 
biological processes makes it a crucial connecting point for many hematopoietic diseases 
like myelofibrosis and myeloproliferative disorders [123]–[133]. JAK2 is a big protein of 1132 
amino acids in length and contains one pseudo kinase (545-809) and one kinase (849-1124) 
domain. Experiments performed on the kinase (808-1132) domain reveal that heme 
promotes the phosphorylation at Tyr1007/1008. Phosphorylation at Tyr1007 is responsible 
for Jak2 activation [82]. But unlike Src kinase, where heme phosphorylates immediately, 
JNK2 phosphorylation takes about 12-30 hours. Like Src kinase, JAK2 also undergoes heme 
induced conformational changes for phosphorylation which are required for continued 
kinase activity [82]. This kinase domain contains one heme binding CP motif located at 1094 
near to Tyr1007 (Figure 9). The binding site for heme is not specifically understood and 
further research needs to be done. 
 
Figure 9: Domain structure of JAK2 kinase with CP motif location and possible heme interaction site (adapted 
from[4]) 
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1.4 Scope of work and publication summary 
This work is part of the DFG-funded researcher group (FOR 1738), a collaborative effort 
addressing four major subjects related to HHDPs: 1) Clinics; 2) Physiology and Cell Biology; 
3) Chemistry and Biphotonics; 4) Biochemistry and Structural Biology, aiming to extend the 
knowledge about the functions of heme and its degradation products in biological systems. 
In the first funding period, heme-peptide interactions were structurally studied. Peptides 
were selected from a combinatorial peptide library for identifying HRMs or favorable heme-
binding sequences in the lab of our collaborator and project partner Professor Diana Imhof 
(University of Bonn). Subsequently, the following biophysical techniques were used to 
characterize the heme interaction: 
1) UV/ Visible spectroscopy was applied to monitor the characteristic Soret band 
(around 398 nm) shift of heme upon peptide binding. Heme upon binding with 
peptide shifts this Soret band either to 370 nm or 420 nm depending on the 
formation of penta or hexa co-ordination with the peptide, respectively.  
2) Resonance Raman spectroscopy was proposed in collaboration with the laboratory 
of Dr. Ute Neugebauer (IPHT, Jena/University Hospital Jena). The resonance Raman 
spectra of free heme gives characteristic five bands in the spectral region between 
1300 and 1700 cm-1. Those five bands are obtained upon excitation of porphyrin ring 
in heme at 413 nm wavelength and named as ν4, ν3, ν2, ν11, ν10. Addition of peptide or 
protein to heme leads to major shifts in ν3, ν2 bands, which shows the heme iron co-
ordination pattern in the heme-peptide complex and proves their interaction. 
3) Finally, NMR spectroscopy was employed to uncover the structure of peptides and 
to map the heme-peptide interactions. Diamagnetic gallium protoporphyrin IX was 
used as the substitute for paramagnetic heme (iron protoporphyrin IX), to avoid the 
paramagnetic effect of iron heme. This paramagnetic effect may lead to large spectral 
widths and severe line broadening, ultimately resulting in reduced or vanishing 
signals in NMR spectra. 2D NMR experiments were performed to derive the structure 
and dynamics of peptides and peptide-heme complexes. 
Based upon above analysis, three major HRMs classes containing eight subclasses 
(shown in Table 2) have been classified. 
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Table 2: HRMs classes 
Number Classes Sub Classes 
1 Cysteine based 
▪ Cysteine only 
Without Histidine or Tyrosine   (Class I) 
With Histidine or Tyrosine        (Class II) 
▪ Cysteine-Proline Without Histidine or Tyrosine (Class III) 
With Histidine or Tyrosine       (Class IV) 
2 Histidine based Without Histidine or Tyrosine  (Class V) 
With Histidine or Tyrosine        (Class VI) 
3 Tyrosine based Without Histidine or Tyrosine (Class VII) 
With Histidine or Tyrosine      (Class VIII) 
In this work – encompassing the second funding period of ‘FOR 1738’ – the aim was to 
extend the acquired knowledge to the protein level. 
Surveying the literature on transient heme-protein interaction revealed that very little 
information is available at the structural level describing how heme binds or interacts with 
certain heme-interacting motifs in proteins and regulates their functions and about the 
affinity of this transient or reversible interactions. To further validate the knowledge 
obtained from the peptide studies during the first term of the HHDP project and to translate 
that knowledge to the protein level in the second term of this project, we developed new 
methods for probing protein-heme interactions, and selected new protein targets: the 
uncrystallizable N-terminal region of cystathionine-β-synthase (CBS) and the interleukin-
36 cytokine family. 
All of the molecules were biophysically characterized and subsequently studied by 
NMR spectroscopy to obtain structural information at the atomic level. This also included 
adaptation and extension of NMR experiments for the challenging tasks to characterize the 
transient heme interactions and to study intrinsically disordered molecules or molecular 
sections. 
1.4.1 Publication 1 
CBS is one of the critical enzymes involved in the transsulfuration pathway. CBS possess 
a pivotal position in sulfur metabolism at the homocysteine intersection where it 
determines the fate of methionine to keep or to condense it to nontoxic cysteine (Figure 9) 
[134], [135]. CBS catalyzes the first reaction in the transsulfuration pathway to convert the 
toxic homocysteine to cystathionine utilizing serine in the process. In the second step, 
cystathionine gamma lyase (CGL) converts the cystathionine to cysteine. Both the enzymes 
also produce hydrogen sulfide (H2s), a recently recognized gasotransmitter and vasodilator 
in humans [136], [137].  This produced cysteine is used intracellularly for the protein 
synthesis and the production of a cellular antioxidant called glutathione [138]. Abnormality 
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in the CBS gene causes an inborn autosomal recessive inherited impaired sulfur metabolism 
disease homocystinuria. Homocystinuria was first reported in 1963 in mentally retarded 
siblings in Northern Ireland [139]. It is characterized by increased homocysteine, reduced 
cysteine and cystathionine concentration in plasma [140]. Elevated levels of homocysteine 
affect majorly four central organ systems, the ocular, skeletal, cardiovascular and central 
nervous system. If left untreated, homocystinuria leads to pathological conditions like 
neural tube defects, dislocated eye lenses, osteoporosis, connective tissue abnormalities, 
atherosclerosis, and Alzheimer’s disease [141]. 
 
Figure 10: CBS in methionine cycle and transsulfuration pathway 
CBS is a complex modular enzyme of 551 amino acids belonging to the fold type II family 
of the pyridoxal 5-phosphate (PLP) dependent enzymes and naturally present as 
homotetrameric form [134]. CBS is a unique PLP family enzyme which binds to heme and 
its activity is regulated by three cofactors: heme, pyridoxal 5-phosphate (PLP) and the 
allosteric activator S-adenosyl-L-methionine (Adomet) [135], [142]. It contains the N-
terminal heme-binding domain, a central catalytic domain and a C-terminal regulatory 
domain. The N-terminal heme-binding domain is 70 amino acid long and contains a 
canonical heme binding site where heme-B binds to cysteine-52 and histidine-65 tightly in 
a hexa-coordinated manner [142]. The central catalytic domain binds to the cofactor PLP 
via a Schiff bond to the K119 residue [143]. The C-terminal regulatory domain contains two 
CBS domains also called as Bateman module where the allosteric activator, Adomet binds 
and activates the enzyme (Figure 11) [144], [145].  
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Figure 11: Domain structure of CBS showing potential heme binding site  
Heme bound at position C52/H65 is suggested to be involved in redox sensing [146] and 
the folding of enzyme [147]. Kery et al. demonstrated that binding of heme to CBS increases 
the specific activity of this enzyme and suggested that heme binding can induce favorable 
conformational changes for PLP binding [142]. This was further confirmed by Ojha [148] 
where they showed that a pathogenic mutation of H65 leads to loss of heme binding 
affecting the catalytic activity of enzyme. In 2002, Oliveriusová  conducted deletion 
mutagenesis studies on CBS and showed that deletion of first 1-39 residues resulted in 
approximately 52% of less active  compared to wild-type CBS [149]. The N-terminal region 
of CBS is very diverse in all the species and, interestingly, X-ray structures are missing for 
the first 42 residues. This suggests that this molecule region to be disordered. However, this 
region is close to the canonical heme-binding site (C52/H65) and sequence analysis showed 
this region containing a CP motif with histidines (H) in its vicinity. We speculated that it 
could be a potential heme-binding motif because of its proximity to the canonical heme-
binding motif and might be involved in enzyme activity. Additionally, sequence alignment 
of this protein further confirmed that the CP motif is conserved in many eukaryotic 
organisms. As discussed previously, CP motifs found in IDP or IDPRs can act as potential 
heme-binding motifs, which bind transiently and regulate the molecule function.  In this 
context we studied this molecule as described in Publication 1.  
1.4.2 Publication 2 
The heme-protein interactions are usually studied via techniques like surface 
UV/Visible, surface plasmon resonance, resonance Raman and NMR spectroscopy [150], 
[151]. The transient nature of this heme-protein interaction makes it difficult to map it at 
atomic level. NMR spectroscopy has been proven a useful tool for mapping such 
interactions and studying specially IDPs/IDPRs.  
NMR spectroscopy, a method to obtain structural information on IDPs/ IDPRs  
▪ Considering the nature of transient interaction of heme with proteins (in the µM 
range), NMR is the only tool that can provide information at atomic resolution of 
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this interaction unlike X-ray crystallography, which can be employed for tight 
binding processes only. 
▪ Homo- and hetero-nuclear multidimensional NMR experiments can deliver protein 
dynamics information upon heme interaction in IDPs and structured proteins while 
revealing the binding mode and surrounding scaffold. 
▪ Solution-state NMR is a useful technique for structural characterization of 
intrinsically disordered proteins (IDPs) because X-ray crystallography does not 
deliver electron densities for these IDPs. The flexible nature of these IDPs or 
intrinsically disordered regions in proteins (IDPRs) renders them hard to crystalize, 
resulting in missing structural data for parts of such proteins. 
During the above studies (publication 1) we found that the classical 2D [1H,15N]-HSQC 
experiment (protein finger printing spectra) has some limitations: exchange sensitivity and 
unability to detect all range of transient interactions. The [1H,15N]-HSQC experiment yields 
information on NH groups in a protein backbone or in other words, the effect of heme was 
observed at the protein backbone level. Generally, side chains are more exposed in solution 
than the backbone of a protein and this idea leads us to develop further NMR experimental 
protocols, the HCBCACON experiment for enhanced sensitivity as compared to the 
conventional 2D [1H,15N]-HSQC experiment as described in publication 2. Specifically, in 
IDPs, inter-residue 15Ni13COi-1 chemical shift correlation spectra have a relatively higher 
spectral resolution as compared to intra-residue correlations [152], [153] and has been used 
to achieve resonance assignment. In this new experiment we were looking for the effect of 
heme on side chains, involving the excitation of side chain either via a coherence transfer 
pathway to directly detect 13CO, called carbon detection, or the transfer pathway to detect 
1H, called proton detection (Figure 12). The HNCBCACON experiment has many 
advantages over the [1H,15N]-HSQC: it can detect ultra-transient heme interaction, studies 
can be done under physiological conditions in terms of temperature and pH with good 
signal to noise ratio. In addition, it also yields proline residue information, which is useful 
to monitor cysteine-proline (CP) motif interaction with heme, which was missing in 
conventional 2D [1H,15N]-HSQC experiments but can be readily seen with good signal to 
noise ratio. 
 
Figure 12: Transfer pathway for HCBCACON experiment 
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1.4.3 Publication 3 and 4 
In publication 3, we have described our second potential heme-binding protein, 
interleukin-36α (IL-36α). This protein was identified during combinatorial peptide studies. 
IL-36α belongs to the IL-36 subfamily of the IL-1 cytokine superfamily. IL-1 is a broad 
cytokine family and has eleven members, IL-1α, IL-1β, IL-1Ra, IL-18, IL-33, IL-36α, IL-36β, 
IL-36γ, IL-36Ra, IL-37 and IL-38 [154]. This interleukin-36 subfamily was discovered more 
than a decade ago and has five members IL-F6, IL-F8, IL-F9, IL-F5, IL-F10, which now are 
known as IL-36α, IL-36β, IL-36γ, IL-36Ra (Receptor agonist) and IL-38, respectively [155], 
[156]. IL-36α, IL-36β, IL-36γ have pro-inflammatory activity and control the induction of 
other inflammatory mediators like chemokines, cytokines (IL-6, IL-8) and antimicrobial 
peptides [157], [158]. They all bind to the same IL36R receptor and recruit IL-1RacP 
(Interleukin-1 receptor associated protein), which together form a heterodimer and activate 
downstream NF-Kappa-B and MAP kinase pathways during pro-inflammatory response in 
target cells (Figure 13) [159]. IL-36α, IL-36β, IL-36γ are secretory proteins and so far no leader 
or signal peptide has been identified for their localization outside the cell [160]. They 
require proteolytic processing of their N-terminal pro-peptides for their full activation [161]. 
The identified neutrophil proteases are cathepsin G and elastase for IL-36α processing, 
again cathepsin G for IL-36β, and proteinase-3 and elastase for IL-36γ processing [162]. IL-
36α processing requires truncation of the first five amino acids, while in IL-36β the first four 
amino acids and IL-36γ the first seventeen amino acids are removed for full activation 
(Figure 13). This processing can lead to an increase in IL-36 enzyme activity from 1,000-
10,000 times compared to full-length proteins [161]. There is not much known about these 
cytokines’ molecular mechanism. They are expressed in skin keratinocytes but increased 
expression has been seen during psoriasis condition in skin lesions [163]. Psoriasis is an 
autoimmune chronic disease characterized by scales and sometimes painful red patches on 
the skin [164]. Recently, IL-36 cytokine family members were also suggested to be involved 
in pregnancy complications [165]. 
 21 Introduction 
 
Figure 13: (A) IL-36 signaling pathway (B) Domain structure of the IL-36 family members and respective proteases     
responsible for truncation of the pro-peptide. Potential heme binding amino acids also highlighted. 
 
IL-36α is a small protein of 151 amino acids and belongs to the HRM class III and IV 
(Table 2). The presence of a CP motif with H and Y renders it a potential heme-binding 
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candidate. This CP motif is also conserved in homology of several other organisms, such as 
mice. Multiple sequence alignment of IL-36 family members showed that the CP motif is 
only conserved in IL-36α and absent in IL-36β and IL-36γ. However, initial studies suggest 
that all three members, IL-36α, IL-36β and IL-36γ are binding to the heme. A detailed study 
of the IL-36α–heme interaction has been described in this paper, involving a series of 
biophysical techniques like UV/ Vis, Raman, SPR, NMR spectroscopy. Initial functional 
studies showed effects of IL-36α-heme interaction on the induction of other cytokines. 
During our study we found that not only IL-36α but also IL-36β and IL-36γ can bind to 
heme. As mentioned above, the CP motif is only present in IL-36α, while the other two 
proteins have QP residues. However, they all contain H and Y residues in the vicinity. We 
hypothesized that heme might be interacting directly or with its propionate side chains via 
electrostatic interaction with other amino acids. This made us to further investigate HRMs 
involved in these two cytokines. We started the investigations with IL-36β because the IL-
36γ structure is already available (PDB code 4IZE). In bone marrow derived dendritic cells 
(BMDCs) IL-36β is solely responsible for the phosphorylation of the p38MAPK activation 
[166], while IL-36γ activates MAPKs, JNK, ERK and p38 MAPK, as well as NF-kB and CREB 
transcription factors in bronchial epithelial cells [165], [167]. IL-36γ also promotes the 
production of interferon- γ (IFN-γ) in CD8+ T-cells and act as anti-tumor immune therapy 
in melanoma and lung cancer [168].  
Aiming to determine the structure of IL-36β as a first step, we performed and published 
the chemical shift assignment of IL-36β isoform 2 (publication 4). Section (further 
results) shows the preliminary results of structure characterization of IL-36β using CD and 
NMR spectroscopy. Additionally, heme-binding studies were also performed on wild-type 
and mutant proteins of IL-36β and IL-36γ using UV/visible and NMR spectroscopy 
techniques. 
 
 
  
 23 Publications 
2 Publications 
 
2.1 Heme interaction of the intrinsically disordered N-terminal peptide 
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authors reviewed the manuscript. OO and DI conceived the 
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Status: Published in Scientific Report (2018) 
https://doi.org/10.1038/s41598-018-20841-z 
 
Summary:              
 
This publication shows the transient interaction of heme with 
the intrinsically disordered N-terminal region (40 amino acids) 
of CBS. Heme interacts with this region through specific 
heme-binding motifs and constitutes for 30% of enzyme 
activity as demonstrated through an in vitro assay. NMR 
spectroscopy was employed to uncover the structural details of 
this region which X-ray failed to provide and revealed the 
second heme binding site with moderate heme binding 
constant.  
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Status: Submitted to Journal of Magnetic Resonance (Under revision) 
 
Summary:              
 
This paper describes the new NMR pulse development for 
probing heme-IDP interactions and assignment of IDPs. This 
experiment detects the effect of heme on the side chains of 
proteins unlike the [1H,15N]-HSQC experiment which shows 
the effect only on the protein backbone. This technique makes 
it more sensitive over the conventional [1H,15N]-HSQC 
experiment to map the heme-IDP interactions and in addition, 
can also be performed at physiological temperature. It can be 
employed as a complementary powerful experiment for 
probing heme-protein interactions to other conventional 
methods. 
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Status: Submitted to Scientific Report 
 
Summary:              
 
This study reports for the first time heme regulation of 
interleukin-36 family members with the detailed experiments 
on interleukin-36α (IL-36α) protein. This manuscript describes 
the NMR solution structure of the IL-36α protein and 
structural binding details with its receptor. This paper also 
presents heme binding studies using NMR, UV/Vis, Raman 
spectroscopy to uncover the involved heme-regulatory motifs 
along with biological test to demonstrate the negative 
regulation of IL-36 mediated signaling by heme.  
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2.4 1H, 13C, and 15N resonance assignments of the cytokine interleukin-36β 
isoform-2. 
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Summary:              
 
IL-36β cytokine is a member of IL-36 family and involved in 
the expression of other inflammatory mediators like 
chemokines, cytokines (IL-6, IL-8) and growth factors. Recent 
studies show their involvement in psoriasis, inflammation, 
rheumatoid arthritis and pregnancy. This manuscript reports 
the NMR resonance assignments for the backbone and 
sidechain atoms of Interleukin-36β isoform-2 (IL-36β). The 
manuscript is providing the bases for future determination of 
the NMR solution structure and mapping of the heme-binding 
motifs in IL-36β.  
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3 Further results 
In this section data will be presented in continuation of the studies described in 
publication 4. 
3.1 HRMs investigations of IL-36β and IL-36γ 
3.1.1 Protein expression and purification of recombinant IL-36β and IL-36γ 
The expression and purification protocol for IL-36β protein has been described in 
publication 4. The synthesized IL-36γ gene containing a caspase-3 site (DEVD) was 
obtained from Eurofins Genomics. The IL-36γ gene was further sub-cloned into the pET28a 
vector between NdeI and XhoI restriction sites and its sequence was confirmed with DNA 
sequencing. The pET28a_IL-36γ plasmid was transformed into the BL21(DE3) competent E. 
coli cells. One colony was inoculated into 250 ml Luria Bertani (LB) medium and allowed 
to grow at 37 °C until optical density (O.D600nm) reached 1.4. Cells were spun down at 5000 
r.p.m. and LB supernatant was discarded. Cells were resuspended in M9 medium containing 
15NH4Cl and 13C6-glucose for the 15N and 13C labeling of protein. Cells were allowed to 
acclimatize in M9 medium for 15 minutes before the IPTG (isopropyl-1-thio-D-
galactopyranoside) induction. Cells were induced with 0.6 mM IPTG and transferred into 
an 18 °C incubator shaker for overnight expression. Expressed cells were spun down at 5000 
r.p.m. and resuspended in a lysis buffer containing 50 mM Tris/HCl, 300 mM NaCl, 5 mM 
imidazole and 5 mM β-mercaptoethanol (pH 8), followed by three rounds of lysis with the 
French press. Lysed cells were centrifuged at 7500 r.p.m. at 4 °C. The clear supernatant of 
cell lysate was applied to a pre-equilibrated Ni-NTA agarose resin with lysis buffer and 
allowed to flow with the gravity. The resin was washed with 10 column volumes each of lysis 
buffer and wash buffer containing 10 mM. Ultimately, the protein was eluted with elution 
buffer containing 0.25 M imidazole. The eluted protein was dialyzed overnight at 4 °C in 
dialysis buffer containing Hepes 50 mM, 75 mM NaCl, 2 mM DTT (pH 7.4) to remove the 
N-terminal His tag using in-house expressed caspase-3 protein (40:1). Next day, the digested 
protein was passed through the pre-equilibrated (using dialysis buffer) Ni-NTA agarose 
resin to bind the remaining undigested IL-36γ protein and caspase-3 protein. This mixture 
was allowed to flow with the gravity and the flow through containing digested protein was 
collected. Remaining digested protein was collected with the same dialysis buffer. All the 
digested protein was concentrated to 1 ml using a 3-kDa amicon filter and injected on a size 
exclusion chromatography column (GE Healthcare) 16/60 Hiload S75. The fractions 
containing pure IL-36γ were pooled together and concentrated using a 3-kDa amicon filter. 
Later the protein was dialyzed into 20 mM sodium phosphate buffer, pH 7.2 for the further 
experiments. The final protein was either used directly for experiments or lyophilized for 
later use.  
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3.1.2 Circular Dichroism (CD) spectroscopy of IL-36β and IL-36γ 
CD spectroscopy was initially employed to obtain a preliminary idea about the 
conformation or secondary structure elements in the IL-36β and IL-36γ proteins. The CD 
spectrum of proteins in the far ultraviolet region can usefully disclose information about 
secondary structure elements. The method has many advantages such as smaller amount 
of protein required, label free samples and fast result about secondary structure. Usually, a 
218 nm negative band represents the  sheet structure while a band around 197 nm indicates 
a random coil structure in a protein. A Jasco J-710 spectropolarimeter with Peltier 
thermostat was used to obtain the far UV range (260 nm-190 nm) spectrum of both the 
proteins. A 1-mm pathlength cuvette was used containing 15 µM of each protein sample. 
The protein was kept at 20 ± 0.3 °C temperature at a 20 nm/min scan speed, bandwidth of 
1.0 nm with a 1.0 nm of resolution and 4 seconds of response time. 
 
Figure 14: The CD spectra of (A) IL-36β and (B) IL-36γ in the far UV range. 
Obtained CD data was further analyzed using two online secondary structure 
prediction servers, CAPITO  (CD Analysis and Plotting Tool) [169] and BeStSel (Beta 
Structure Selection) [170]. The CAPITO algorithm utilizes the existing validated CD spectra 
from the Protein Circular Dichroism Data Bank (PCDB) while BeStSel takes an advantage 
of already available structures in the Protein Data Bank (PDB) and the CATH- protein 
structure classification database. Analyzed data can be seen in table 3 below. 
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Table 3: Secondary structure element analysis of IL-36β and IL-36γ 
Protein Server α-helix β-sheet Irregular 
IL-36β CAPITO 31 54 15 
 BeStSel 12.4 62.2 25.4 
IL-36γ CAPITO 32 53 14 
 BeStSel 12.4 62.2 25.4 
 X-ray 12 45  
When comparing the results with the secondary structure content of the X-ray 
structure of IL-36 as comparison standard BeStSel gives a more correct estimation of the 
α-helix while CAPITO more correctly describes the β-sheet content. The CD analysis shows 
that the generated constructs IL-36β and IL-36γ basically display the same content of α-
helix and β-sheet content. 
3.1.3 NMR solution structure of the IL-36β protein 
For the calculation of the NMR solution structure of IL-36β nuclear Overhauser 
enhancement distances (NOE) and torsion angle constraints were used. Three-dimensional 
[1H, 1H, 15N]-NOESY-HSQC and [1H, 1H, 13C]-NOESY-HSQC experiments were used to 
extract NOE-derived distance restraints, spectra were recorded at 20 °C using 1 mM 1H, 13C, 
15N labeled IL-36β protein samples prepared in 90% H2O 10% D2O and 100% D2O, 
respectively. The Varian 900 MHz NMR system equipped with 5mm triple resonance cryo-
probes. Referencing of C and N was performed via indirect chemical shift referencing. 
Processing of spectra was performed using TOPSPIN V2.2 (Bruker software) and for NOE 
assignment the CCPNmr analysis tool [171] was used. 
The preliminary structure of IL-36β was generated using CYANA 3.98.5 [172], [173] 
where a total of 9225 unambiguous distance restraints (3955 15N-NOE and 5270 13C-NOE) 
were employed in the calculations. From 100 structures started with random angle 
distributions the best 20 solutions were selected for further energy minimization using two 
programs firstly OPAL [174] and secondly SYBYL (Certara St.Louis, US). The energy 
statistics of the final ensemble of 20 energy-minimized structures (Figure 28 in discussion) 
are shown in table 4. 
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Table 4: Energies of best IL-36β molecule 
Bond Stretching Energy 26.928 
Angle Bending Energy 210.642 
Torsional Energy 163.445 
Improper Torsional Energy  4.111 
1-4 van der Waals Energy 268.817 
van der Waals Energy -963.745 
H-Bond Energy 0.000 
Total -289.803 kcals/mol 
The inspection of the initial NMR solution structure of IL-36β displays the typical β-
trefoil fold similar to those found for other cytokines in the IL-1 family [175], [176]. Detailed 
structural comparisons are shown in the discussion section. 
3.1.4 UV/Visible spectroscopy of heme with IL-36β and IL-36γ 
As mentioned previously, heme shows a characteristic Soret band shift upon protein 
interaction in UV/Vis spectroscopy [177]. The Cary series UV/Vis spectrophotometer of 
Agilent technologies was employed for the measurement in the range of 250 nm to 800 nm 
using a 1-cm pathlength cuvette. A heme stock solution of 4 mM was prepared in 0.2 N 
NaOH solution and titrated against 5 µM of IL-36β and IL-36γ in 20 mM sodium phosphate 
buffer (pH 7.2) in equimolar concentration.  
The UV/Vis spectra of the heme-IL-36β complex shows the Soret band shift towards 
420 nm while the heme-IL-36γ exhibits a Soret band shift towards 370 nm which 
corresponds to hexa- and penta-coordination, respectively (Figure 15). 
 
Figure 15: The UV/Visible spectroscopy absorbance spectra: (A) IL-36β-heme and (B) IL-36γ-heme 
complex 
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3.1.5 Resonance Raman spectroscopy of IL-36β-heme complex 
A Horiba Jobin-Yvon LabRam HR 800 Raman spectrometer (Horiba, Kyoto, Japan) was 
used to obtain information on the heme coordination pattern in the IL-36β-heme complex. 
This device was equipped with a back-illuminated deep-depletion CCD detector (1024 × 256 
pixels) cooled using liquid nitrogen. A Coherent Innova 300C ion laser was applied through 
the krypton line at 413.1 nm for excitation of Raman scattering. An Olympus BX41 upright 
microscope (Olympus, Tokyo, Japan) was connected to this Raman assembly to focus the 
incoming laser light onto the sample and also to collect the 180° backscattered light using 
a motorized XY microscope stage and a 20x objective (Olympus UPlanFL N, NA 0.50). The 
phosphate buffered NaCl, pH 7.0 was used for the preparation of the heme sample (400 µM) 
and the heme-protein sample in equimolar concentration (400 µM). The heme solution 
used here was prepared as described in publication 3. The heme-protein reaction mix was 
incubated at room temperature for 60 min in the dark and centrifuged before the 
measurement to remove any precipitant in the solution. 
The 413 nm wavelength was applied to excite the heme moiety alone or heme-protein 
complex to gather the information of two spectral regions 1) Lower wavenumber region 2) 
Higher wavenumber region at a spectral center of 750 and 1400 cm-1. The moderately 
increased band ν7 and decreased band ν3 around 1492 cm-1 indicated the penta-coordination 
pattern in the protein-heme complex [178]–[181]. In general, the Raman spectra showed IL-
36β to bind to heme predominately in a penta-coordinated complex (Figure 16).  
  
 
Figure 16: Superimposed resonance Raman spectra of IL-36β-heme complex (red) and heme (black). (A) 
Lower wavenumber region (B) High wavenumber region with frequencies indicated 
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3.1.6 NMR spectroscopy of IL-36β and IL-36γ protein (wild type and mutant 
proteins) with heme 
The [1H,15N]-HSQC experiment was used for the monitoring of IL-36β and IL-36γ 
protein interaction with heme. The 4 mM heme solution was prepared in 0.2 N NaOH and 
100 µM of protein dissolved in 20 mM sodium phosphate buffer, pH 7.2, at 20 °C for these 
measurements. 
3.1.7 IL-36β interaction with heme 
The IL-36β protein sample (100 µM) was measured alone and with the addition of 50 
µM of heme. Upon addition of heme no chemical shift changes were observed, only selected 
residues intensities were either attenuated or completely disappeared (G130, Q131, S126, A28 
and side chain of N56) (Figure 17). These residues were mapped on the initial IL-36β 
structure which revealed the effect of heme at two sites. To determine the exact heme-
binding motifs we decided to produce protein mutants. Using site directed mutagenesis 
with complementary primers in total six mutant IL-36β proteins (H104A, Q131V, Q131E, 
Q131G, P132G and N56G) were produced in same way as described for wild type for NMR 
mapping experiments. 
Interestingly, inspection of the NMR spectra revealed that the previously speculated 
heme binding at H104 which corresponds to H109 in IL-36α seemed not to be affected 
compared to effects at other residues (Figure 18). This was further confirmed as the H104A 
mutant showed heme binding similar to that observed for the wild type IL-36β protein. 
Q131V mutants were created which resulted in heme binding as in the wild type protein. 
This suggests that the valine in the Q131V mutant might mediate an interaction with heme. 
To test this theory of an interaction via valine in Q131V we created two mutants: 1) a Q131E 
mutant which shares a sterically similar side chain structure with glutamine and 2) a Q131G 
mutant which lacks a sidechain. The Q131E mutant also showed heme binding which was 
not as prominent as in wild type and in the Q131V mutant. An effect could be still seen at 
G130 and N56δ (side chain) while the Q131G mutant abolished most of signal changes 
characteristic for heme binding except at N56δ (side chain) (Figure 18). This suggests that 
heme binding can also be mediated by side chain interactions of Gln, Val, Asp and Asn. To 
check the contribution of N56 we created a N56G mutant which resulted in abolition of 
heme binding even at the Q131 residues (Figure 18). Thus, it might be possible that heme 
binding at N56 favors the binding at Q131P132 site.  
In order to check a supporting role of P132 we created the P132G mutant which showed 
the less intensity reduction upon heme binding as compared to wild type which suggests 
that heme binding effects were reduced (Figure 18). This confirms the supporting role of 
P132 in heme binding at Q131 as in the CP motif as shown in IL-36α (publication 3). This 
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evidence clearly supports heme binding in Il-36 at Q131P132 as well as N56. The result is in 
also accordance with the observation of SPR studies that two molecules of heme bind to 
one molecule of protein. 
 
 
Figure 17: Superimposition of the [1H,15N]-HSQC spectrum of 100 µM IL-36β protein without (blue) and 
with 50 µM heme (red). Affected residues are indicated.  
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Figure 18: Superimposition of the [1H,15N]-HSQC spectrum of 100 µM IL-36β mutant proteins without (blue) and 
with 50 µM heme (red) (A) H104A, (B) Q131V, (C) Q131E, (D) P132G, (E) Q131G, (F) N56G. 
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3.1.8 IL-36γ interaction with heme 
To obtain a complete overview of heme binding in the IL-36 family we performed also 
NMR measurements with IL-36. [1H,15N]-HSQC spectra of IL-36γ (100 µM) were acquired 
with and without the of heme addition. Consistent with IL-36β no chemical shift changes 
were observed upon 50 µM heme addition. However, again reduction of some peak 
intensities was observed (Figure 20). As mentioned previously the X-ray structure of IL-36γ 
is already available (PDB code 4IZE) which allowed a mapping without undergoing a 
complete NMR structural analysis. A mutation strategy was used to uncover the HRMs in 
IL-36γ without performing an extensive NMR resonance assignment. The mutant proteins 
of IL-36γ were prepared after examining its X-ray structure and taking into account its close 
sequence similarity with the IL-36β protein (Figure 19).  
 
 
Figure 19: Sequence alignment of IL-36β and IL-36γ showed 43% sequence identity (Clustal 2.1). Suggested heme-
binding sites marked in color. 
Mutants Q130V, Q130E, Q130G and D56G were created. These mutant proteins upon 
heme addition showed a similar behavior to the mutant proteins produced for IL-36β 
(Figure 21). Q130V and Q130E mutants display a higher intensity reduction and more 
residues were affected as compared to the Q130G mutant. This suggests Q130 as the one 
possible heme binding site as observed for IL-36β. The IL-36β has N56 as second heme 
binding site whereas in IL-36γ at this position resides a D56 residue. To test if this aspartate 
residue has the potential for heme binding, a D56G mutant was created. This mutant 
showed an intensity reduction at few residues and similar to the IL-36β N56G mutant 
almost abolished the heme binding of the whole molecule (Figure 21). Again, the possible 
explanation for this observation could be the same as in IL-36β where binding at the D56 
site favors the binding of heme at the Q130P131 motif. This evidence suggests the possible 
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role of Q130P131 and D56 in heme binding which coincide with the SPR results of two heme 
molecules binding to one molecule of IL-36γ. The most affected residues are marked by an 
arrow in figure 21 and are further discussed later in this discussion section. 
 
 
Figure 20: Superimposition of the [1H,15N]-HSQC spectrum of 100 µM IL-36γ protein without (blue) and with 50  
µM heme (red). Strong intensity reductions can be seen at the marked (arrow) affected residues 
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Figure 21: Superimposition of the [1H,15N]-HSQC spectrum of 100 µM IL-36γ mutant proteins without (blue) and 
with 50 µM heme (red) (A) Q130V, (B) Q130E, (C) Q130G, (D) D56G. Most affected residues are marked with 
arrow. 
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4 Discussion 
In the last two decades the regulatory or signaling role of heme came under light in 
different biological processes where heme binds transiently to HRMs in proteins. Although 
a classification of HRMs has been proposed in the last years based on the case where an 
iron moiety in heme directly binds to cysteine, histidine, tyrosine [80], not all HRMs have 
been identified. In this study we have gained evidence that not only the central iron atom 
of heme but also propionate side chains can mediate a binding to amino acid residues 
through electrostatic or other weak interactions. These new identified HRMs will add 
knowledge to the growing structural HRMs classification and help to understand yet 
unidentified heme regulated proteins in biological processes. 
4.1 N-terminus of the intrinsically disordered region (IDPR) of human 
cystathionine-β-synthase (CBS) (Publication 1) 
The human CBS enzyme belongs to the large family of PLP dependent enzymes (EC 
4.2.1.22), which is involved in the first step of the transsulfuration pathway thereby 
converting toxic homocysteine to cystathione. It is the only unique PLP-containing enzyme 
that has heme as a second cofactor. Deficiency or mutation of this enzyme leads to 
homocystinuria, an inherited disease. Characterized by elevated levels of toxic 
homocysteine in blood plasma this leads to many fatal pathological conditions in the 
cardiovascular, ocular, skeletal, and central nervous system e.g. in neural tube defects, 
cardiovascular diseases and Alzheimer’s disease [182]–[184]. 
CBS has an N-terminal canonical heme binding domain followed by a catalytic core, 
which is conserved in most proteins of this class of organisms, and a C-terminal regulatory 
domain (Publication 1, Figure 1). For the first time, in publication 1 we have shown that 
apart from canonical (covalently) heme binding at C52 and H65, heme also interacts 
transiently to a CP motif consisting of C15P16 and H22 via hexa-coordination. This allows 
heme to act via a second independent heme-binding site and this transient interaction of 
heme constitutes for approximately 30% of the enzyme activity. This effect was shown using 
a CBS protein activity assay on wild-type CBS and its mutant proteins. A series of NMR and 
UV/Vis spectroscopy experiments have been performed to structurally define this transient 
heme interaction. 
4.1.1 Production of CBS (1-40 amino acids) protein 
The N-terminal region of CBS (amino acids 1-40) responsible for the gain in enzyme 
activity mentioned above is intrinsically disordered as deduced from our NMR studies and 
supported by the absence of this stretch in X-ray structures. IDPs are prone to proteolytic 
cleavage during expression and purification [185]–[187]. To obtain the stable CBS (1-40) 
region, a fusion approach with the streptococcal protein GB1 was used. GB1 is the commonly 
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used tag to improve the solubility of small peptide and proteins. This tag is inert in nature 
and does not interfere with its fusion partner. Additionally, it also lacks cysteine and 
histidine as binding residues for heme interactions which was further confirmed by NMR 
experiments performed on GB1 alone with heme that proved no interaction. A NMR 
assignment experiment (3D HNN) performed on GB1CBS(1-40) also revealed that the 
assignment of CBS can be easily performed without being hindered by spectral overlap of 
GB1 fusion protein peaks (Publication 1, Figure S1). The GB1 signals were mostly filtered 
out during the 3D HNN NMR experiment because the free induction decay (FID) signals of 
the rigid structured GB1 domain die fast, while the flexible nature of CBS(1-40) results in 
longer lasting FID and recordable signals (Figure 22). Thus, a spectral overlap problem of 
the fusion tag can be avoided without the need of complex and time-consuming segmental 
unlabeling techniques [188], [189].  
 
Figure 22: Diagrammatic representation of FID and relaxation time in structured and intrinsically disordered 
proteins (IDPs) 
4.1.2 Heme-GB1CBS(1-40) interaction studies   
After obtaining stable GB1CBS(1-40) we have used the conventional 2D NMR [1H,15N]-
HSQC experiment (protein finger printing) for monitoring of the heme interaction. The 
resulting spectra showed no chemical shift changes, only a reduction of peaks intensities 
was observed with the maximum reduction at C15 and surrounding residues (T13, G14, C15, 
H17, R18, S19, H22, S23). This indicated the spatial proximity of paramagnetic iron (heme) 
to these residues and was in agreement with the Soret band shift near 420 nm in UV/Vis 
spectroscopy. This 420-nm shift indicates the protein binds to heme in hexa-coordinated 
geometry (Figure 23). We have also observed similar intensity reductions upon binding 
experiments with diamagnetic Ga-PPIX, which is a substitute of paramagnetic Fe-PPIX 
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(Publication 1, Figure 5b). This explains that Fe-PPIX has not only a paramagnetic 
relaxation effect (PRE) but also exerts an exchange contribution upon heme binding. The 
effect of Fe-PPIX PRE can be seen up to ~ 12 Ångstrom (Å) [190] explaining the maximum 
intensity reduction at C15 to H22 where heme binds as well as residues apart from this site 
(S3, Q40) with a reduced effect (Publication 1 Figure S3). This is in accordance with Clore 
et al. who have defined transient protein-DNA interactions with lifetimes spanning 
nanoseconds to milliseconds using PRE effects [191], [192]. The single point mutation at C15 
leads to abolition of heme binding in [1H,15N]-HSQC spectra. Again, this is in agreement 
with UV/Vis spectroscopy, which shows no Soret band maxima at 370 nm or 420 nm. This 
underlines the involvement of C15 in transient heme binding in a hexa-coordinated complex 
together with H22 as other axial ligand site. The involvement of H17 can be excluded due to 
insufficient residue spacing to form a hexa-coordination loop. However, the point mutation 
at H22 shows no significant intensity reduction in the [1H,15N]-HSQC spectra upon heme 
addition, while UV/Vis spectra displays a Soret band at 370 nm. This suggest that heme 
binds to C15 very weakly or the rate of exchange between heme-bound and free GB1CBS(1-
40) is not in a favorable range on the PRE time scale [80], [191], [192]. In general, heme binds 
to CBS(1-40) peptide via C15 and H22. Thereby, the peptide undergoes a conformational 
change to form a hexa-coordinated complex. This is reflected and further supported by an 
enzymatic assay done on the CBS(1-413) and CBS(1-413)_C15S mutant proteins which shows 
that the mutant protein has approx. 30% less activity than the wild type. The same type of 
activity reduction was observed by Oliveriusová upon deletion of CBS(1-39) residues 
(Oliveriusová, Kery, Maclean & Kraus, 2002) and several other studies also pointed out the 
importance of heme in activity of CBS enzyme [142], [148].  
 
Figure 23: Cartoon illustration of CBS(1-40) forming hexa-coordination through cysteine 15 and histidine 22 with 
the central iron atom of heme 
This flexible N-terminus peptide either act as second independent transient heme 
binding site apart from the canonical covalent heme binding site or its flexible nature make 
it as a heme scavenger for canonical heme binding site as depicted in (Figure 24). This 
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GB1CBS(1-40) study also stresses that we need to consider the complete molecule for full 
functional description as during X-ray studies often these flexible or disordered regions 
which can serve as potential interaction sites are eliminated from molecules of interest to 
facilitate the crystallization. 
 
 
Figure 24: Cartoon illustration of CBS showing the possible role of the N-terminus (1-40) in context of heme 
4.2 Development of a NMR pulse to study intrinsically disordered protein 
(IDP)-heme interaction (Publication 2) 
The growing number of reports of functionally relevant IDP in the last two decades 
made NMR spectroscopist to develop new pulse programs to study IDP systems at atomic 
level. The classical two dimensional [1H,15N]-HSQC experiment is often used to map 
protein-ligand interactions and we initially also employed this approach for protein-heme 
interaction studies. However, it became clear that this experiment has some limitations at 
physiological temperatures and pH, where signals start disappearing due to increased 
amide proton exchange and limitations in sensitivity. Often protein-heme interactions 
studied by [1H,15N]-HSQC experiments mirror only the effect of heme on the protein 
backbone while the more solvent exposed side chains could provide better interaction data. 
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For instance, we found that the H22L mutant protein of GB1CBS(1-40) shows heme binding 
in UV/Vis spectroscopy but failed to reflect this feature in the [1H,15N]-HSQC experiments. 
This instigated us to further develop a NMR experiment to probe IDP-heme interaction 
more reliably as demonstrated in publication 2.  
The newly modified HCBCACON is a side-chain experiment that yields the information 
of involved side chains upon heme interaction. Here we have exploited the ability of IDPs 
to provide better inter-residue 15Ni13COi-1 chemical shift correlations than intra-residue 
spectra to generate better spectral dispersion and achieve resonance assignment [152], [153]. 
These 15Ni13COi-1 chemical shift correlation spectra were generated by excitation of side 
chains and detecting either 13CO or Hα (Figure 25). This 13CO detection allows a simple 2D 
experiment and, therefore, can be carried out in less time. The heme binding experiment 
carried out using this protocol on GB1CBS(1-40) shows similar residues affected like [1H,15N]-
HSQC experiment. In addition, measurements can be done at physiological temperature 
(37 °C) and also provide information about proline residues which is missing in [1H,15N]-
HSQC experiments. This information is especially crucial when studying heme interactions 
with CP motifs. An additional advantage of this 13CO experiment is that in cases where IDP-
heme interaction studies were carried out with GB1 fusion protein tag at 10 °C, it can reduce 
the large portion of signals originating from the GB1 tag which leads to less spectral 
crowding and unambiguous mapping of the interaction. These studies can also be 
performed using the HCBCACO experiment [193] but the 13CO-detected HCBCACON 
experiment displays a better resolution. The experiment conducted on  GB1CBS(1-40)_H22L 
finally shows the heme interaction and sensitivity advancement over the [1H,15N]-HSQC 
experiment and confirms the UV/Vis study. However, at elevated temperature signals from 
the GB1 tag start appearing because of the increased molecular tumbling rate and less 
relaxation losses of signals. Nevertheless, in cases where the interaction does not lead to 
chemical shift changes it still provides a useful mapping approach even under spectral 
crowding. 
To solve the spectral crowding problem and to obtain more sensitivity, the second Hα 
detection method came to view. This approach employs the same HCBCACON 
experimental protocol to detect the Hα because protons are the most sensitive nuclei 
compared to C and N, instead of 13CO. This Hα detection was implemented as a 3D 
experiment, which is more time consuming. However, utilizing the non-uniform sampling 
technique (REF) allows to compensate for the extended 3D measurement time. Unlike the 
[1H,15N]-HSQC experiment, elevated temperature favors this experiment since increased 
molecular motion leads to increased relaxation times and thus a better signal to noise ratio. 
Improved sensitivity and spectral resolution were demonstrated using this approach not 
only on GB1CBS(1-40) but also on its mutants. The C15 mutants shows no heme binding, 
while H22 mutants shows heme binding which was in accordance with the UV/Vis 
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spectroscopy and proves the improved sensitivity of this experiment over the [1H,15N]-
HSQC experiment. The additional advantage of this experiment is that it can also be run as 
2D if the system has good Hαi-1-15Ni and 13COi-1-1Hi-1 dispersion and that not only the protein-
heme but other protein-ligands interaction can also be mapped in few hours.  
In total, Hα detection using the HCBCACON experimental protocol can be used as a 
robust complimentary approach over conventional [1H,15N]-HSQC and 13CO-based 
experiments [194] at lower or physiological temperature. Initial measurements (data not 
shown) suggest that this experiment can also be used to study protein-heme interaction 
under molecular crowding (which might better mimic conditions in the cellular 
environment).  
 
Advantages: 
▪ Good sensitivity to detect IDP-heme interactions and applicable with GB1 fusion tag 
▪ Can be carried out at physiological temperature (37 °C) and provides proline resonance 
information  
▪ Interaction can be map in few hours 
▪ Can be run as 3D for improved resolution  
▪ Can be used for other IDP-ligand interactions 
Figure 25: Signal transfer scheme of HCBCACON experiment in protein, starting excitation of Hβ and detecting 
at the end (A) CO (B) Hα detection. Mentioned several advantages of HCBCACON over [1H,15N]-HSQC 
experiment. 
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4.3 Interleukin-36α (IL-36α) and its interaction with heme (Publication 3) 
IL-36α is a second protein derived from the peptide-heme interaction studies as a 
potential heme binder. As shown in publication 3, IL-36 family members (α, β, γ) bind to 
heme. Surface plasmon resonance (SPR) and biological tests confirmed the binding of 
heme. However, a detailed study has been performed only on IL-36α in this publication 3. 
Initial UV/Vis experiments on nona-peptides resembling the CP sequence part of this 
protein showed heme binding at CP and YH, which made us to further investigate it at 
protein level. The UV/Vis study on IL-36α displayed Soret band shifts at 370 nm and 420 
nm, which reflected the binding of two heme molecules. This was in accordance with the 
SPR measurements, which also showed a biphasic heme interaction. UV/Vis experiments 
done with only protoporphyrin IX (PPIX) showed no effect on the IL-36α molecule 
confirming the importance of iron for this interaction. Seven mutants were created to 
further confirm the involvement of CP and YH residues in heme binding: Y108S, H109A, 
C136SP137A, Y108SH109A, Y108SC136SP137A, H109AC136SP137A and 
Y108SH109AC136SP137A The UV/Vis of the Y108S mutant resulted in loss of the 370-nm shift 
and a reduced affinity was observed for heme, while the H109A mutant behaved like the 
wild type with the presence of both 370- and 420-nm Soret shifts. However, only minor 
differences in heme affinity were observed which might be explained by a supporting role 
of H109 in binding of heme at Y108. The C136SP137A mutant shows a loss of the 370-nm 
shift confirming the involvement of CP in heme binding. This is further supported by the 
results of the Y108SC136SP137A, H109AC136SP137A and Y108SH109AC136SP137A mutants. 
The loss of ~ 370-nm shift in case of Y108S mutant has not been fully understood. The 
UV/Vis band around 420 nm in all Y108S mutants showed unusual broadening, which might 
indicate the unspecific or less specific binding of heme as shown in earlier studies [48], 
[195]. Involvement of the C136P137 and Y108H109 was clear where P137 and H109 have a 
supporting role in heme binding. The heme dissociation constant determined by SPR and 
UV/Vis spectroscopy reveals that one heme molecule binds at C136P137 with high affinity, 
while another heme molecule binds at Y108H109 with low affinity. 
Raman spectroscopy provided further insight into the geometry of bound heme with 
the IL-36 protein. The wild-type IL-36α-heme complex and its mutant proteins exhibit a 
dominant presence of penta-coordination except the mutant C136SP137A and 
Y108SH109AC136SP137A additionally shows the negligible indication of heme complex. 
4.3.1 NMR spectroscopy of IL-36α-heme interaction 
NMR experiments performed on the full-length and truncated IL-36α show that there 
were no spectral changes upon truncation of the pro-peptide. Binding of heme results in no 
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chemical shift changes. However, for both Ga-PPIX and Fe-PPIX, an intensity reduction at 
selected residues was observed. Mapping of these affected residues on the NMR derived IL-
36α solution structure reveals the presence of these residues in the vicinity of positions 
C136P137 and Y108. This suggests the C136P137 motif as coordination site for one heme 
molecule and attenuation of, e.g., H109 shows the binding of another heme molecule at 
Y108 which is in accordance with the UV/Vis study of the mutants. Molecular dynamics 
(MD) simulations and molecular docking of heme performed on the IL-36α NMR solution 
structure showed that the stereoelectronic conditions for binding of heme at C136 and Y108 
are fulfilled, additionally supporting our experimental data.  
4.3.2 Docking of IL-36α structure on its cognate receptor  
The NMR study performed on full-length and truncated IL-36α indicated no major 
changes of the overall structure upon heme binding. Docking of the IL-36α structure on its 
cognate receptor complex (IL-1 receptor, PDB code 3O4O) showed that the presence of the 
first five N-terminal residues in full length IL-36 hindered the association with the 
receptor complex. After cleavage of these five residues, the shorter N-terminal section could 
be fully accommodated in a molecular cleft thus promoting association with the receptor. 
This explains very well the need for N-terminal processing of the IL-36α pro-peptide for a 
full activation of its molecular function as previously reported in literature [161]. 
4.3.3 Negative regulation of IL-36α-mediated signal transduction 
In vivo studies performed on synovial fibroblast-like synoviocyte (FLS) cells from 
rheumatoid arthritis (RA) patients (data communicated from Hueber group at Erlangen 
University Hospital) showed the impact of IL-36α-heme complex on its signaling. In normal 
conditions, IL-36α binds to its receptor (IL-36R) and stimulates the expression of IL-6 and 
IL-8 cytokines. Pathological conditions [4], [39], [196] where severe hemolysis leads to a 
drastic increase in heme concentration (20 to 350 µM) can abrogate the IL-36α signaling. 
There, binding of heme with IL-36α leads to disabled association with the receptor, which 
in turn is not able to stimulate the expression of IL-6 and IL-8 proinflammatory cytokines 
(Figure 26). The same study performed on all truncated IL-36α mutant proteins showed 
that either the mutation leads to complete loss of activity or that the mutated residues were 
critical for binding to the receptor complex except C136SP137A mutant. The C136SP137A 
mutant showed relatively less but still activity compared to the wild type, suggesting a 
potential role of the Y108H109 motif in heme association and functional signaling. 
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Figure 26: Possible scenarios of IL-36 mediated signaling in normal and pathological conditions (presence of 
heme) 
4.4 Interaction of heme with interleukin-36β (IL-36β) and interleukin-36γ 
(IL-36γ) (Publication 4 & further results) 
As mentioned previously these two cytokines are also a part of the IL-36 family and 
during SPR and biological studies also their heme binding capacity was revealed. Sequence 
alignment of all three cytokines (IL-36α, IL-36β and IL-36γ) reveals that the heme binding 
CP motif is uniquely present in the IL-36α while in IL-36β and IL-36γ CP is replaced by QP. 
The second heme binding site in IL-36α was located at Y108H109, interestingly histidine is 
present in IL-36β while tyrosine is conserved in IL-36γ at same position in IL-36α. We 
speculated that heme might be interacting with QP, Y, H amino acids in IL-36β and IL-36γ 
as shown in Figure 27. Apart from these residues several other potential heme-binding 
amino acids are also present in all three members.  
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Figure 27: Sequence alignment of all three members of IL-36 family cytokines. Suggested heme-binding sites 
marked in color. 
4.4.1 Secondary structure elements in IL-36β and IL-36γ 
Before performing the detailed NMR based structure determination the simple far UV 
CD spectroscopy was used to get an idea about the secondary structure elements of IL-36β. 
The CD spectra of IL-36β showed a high composition of β-sheet as analyzed through 
CAPITO and BeStel which in accordance with the predicted secondary structure content 
from NMR data by the CSI program as discussed in publication 4. The program CSI uses 
the backbone chemical shift assignments of the respective protein to calculate the 
secondary structure information [197], [198]. Comparison of the IL-36α NMR solution 
structure and the X-ray structure of IL-36γ with the predicted CSI results of the homologous 
IL-36β revealed that the location of secondary structure elements in all proteins coincides. 
The chemical shift of all the prolines present in IL-36β revealed an all-trans conformations. 
A result which has been also observed for IL-36α [199]. In addition, the D2O exchange study 
on IL-36β gives additional evidence for the presence of β-sheet arrangements as predicted 
by CD and CSI since many of the residues failed to exchange after three times of D2O 
lyophilization. This suggests the locations of these residues are inaccessible or buried and 
reveals the position of β-strands (Publication 4 figure2). In the NMR literature [200], [201] 
it was reported that a temperature coefficient study can also be used to locate secondary 
structure elements. The temperature coefficients of IL-36 as described in publication 4 
also suggest that some of the affected residues are located on the H-bonded strands or 
helices.  Finally, the CD spectroscopy results of IL-36γ are matching well with the secondary 
structure content derived from the analysis of the X-ray structure. 
4.4.2 NMR solution structure of the IL-36β protein 
An initial 3D NMR solution structure of IL36- was calculated employing the program 
CYANA 3.98.5 and a set of distance restraints based on the initially assigned 15N-NOE and 
13C-NOE cross peaks. The best 20 of 100 calculated structures with lowest target function 
were chosen and further relaxed by energy minimization using the OPAL and SYBYL. The 
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final ensemble of 20 structures has a low root mean square deviation (RMSD) value for the 
backbone atoms of 0.52 Å. 
 
Figure 28: Backbone structure of all three members of IL-36 family (prepared in Mol Mol)  
The preliminary NMR solution structure exhibits the typical β-trefoil fold symmetry 
like observed for the IL-36α NMR solution structure and the IL-36γ X-ray structure with 
~27% of identity shares among them. For visual comparison Figure 28 shows the backbone 
of all three IL-36α, IL-36β, IL-36γ structures in parallel. It becomes obvious that the overall 
fold for all three members are highly similar and contains almost same distribution of β-
strands and α-helical elements. 
4.4.3 Heme interaction study of IL-36β and IL-36γ using NMR spectroscopy 
The [1H,15N]-HSQC spectra were used for the monitoring of IL-36β and IL-36γ 
interaction with heme. The spectra displayed no chemical shift changes in residues position 
only intensity reductions were noticed at special positions. The affected residues were 
mapped on the preliminary IL-36β structure showing that residues around Q131P132 and 
N56 residues (Figure 29) were affected. The NMR studies performed on the wild type IL-
36β and Q131V, Q131E, N56G mutants suggest that the heme is interacting with the side 
chains of this molecule. The wild type IL-36β has Q131P132 as a first heme binding site while 
N56 acts as secondary binding site. It has been shown that amino acids containing nitrogen 
atoms in the side chain like lysine, asparagine [202] with its amide group and in rare cases 
an amino group of proline [203], [204] can act as a axial ligand or interact with the 
propionate groups as shown in (Figure 30). This is also in accordance with Raman 
spectroscopy showing penta-coordination and supports our experimental studies. One 
study reported that often hydrophobic amino acids like valine, leucine, isoleucine and 
alanine are frequently found close to the proximal or distal side of heme where they can 
interact with non-polar propionate groups through hydrophobic interactions [4], [205]. Our 
study suggests that the two methyl groups of valine in the Q131V mutant are able to interact 
with propionate groups of heme through weak hydrophobic interactions. The effect of 
heme in the Q131E mutant was less pronounced as compared to Q131V and wild type IL-36β 
which indicates that the negatively charged COO- group of the glutamate in the Q131E 
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mutant might be directly interacting with the iron (Fe2+/3+) atom of heme through even 
weaker electrostatic or ionic interactions. As reported earlier not only hydrophobic but also 
electrostatic interactions are possible interactions between heme and a protein through 
hydrogen bonds or weaker salt bridges [4]. These conditions also apply to the IL-36γ and its 
mutant proteins where Q130 is the first heme binding site interacting through amide side 
chain. In addition, the second heme interaction site D56 might be interacting through 
weaker electrostatic interactions (Figure with structure). This is further supported by SPR 
data where one heme molecule binds relatively stronger than a second site in both IL-36β 
and IL-36γ molecules (Publication 3, TableS1). The functional aspects of the interaction of 
these proteins with heme have been illustrated previously in figure 26 with IL-36α. 
 
Figure 29: Affected residues upon heme addition indicated in IL-36 family members with blue color while heme-
binding sites marked in orange and khaki  
 
Figure 30: Possible interaction (Red) of heme propionate group with (A) Glutamine (B) Asparagine and (C) 
Aspartate directly interacting with iron atom 
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 In conclusion, to our knowledge for the first time through these in vitro studies we are 
unraveling that glutamine and asparagine can also act as an axial ligand for transient heme 
binding. This adds further potential residues beside the previously reported cysteine, 
histidine, tyrosine, methionine to the interaction repertoire. While the latter are known as 
canonical binding sites for the central iron atom, aspartate, valine and glutamate can 
interact to propionate side chains.  
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5 Future Prospects 
5.1 Human cystathionine-β-synthase (CBS) interaction with heme 
The study performed in this thesis revealed the role of transient heme interaction for 
the enzymatic activity of CBS. Deficiency in this enzyme or loss of function is responsible 
for a disease called homocystinuria. Many pharmacological studies have been performed to 
restore the function of this enzyme caused by pathological mutations [206]–[208]. To 
consider this new transient heme binding functional aspects to further explore the activity 
of this enzyme could strengthen these strategies. One study already suggested δ-
aminolevulinic acid (δ-ALA), a heme precursor, with other small osmolytes were able to 
restore 30% activity of 14 pathogenic CBS mutants [206]. In addition, CBS is also responsible 
for the production of 95% of hydrogen sulfide (H2S) in brain which is recently recognized 
as signaling molecule and to have implications in cardiovascular and nervous systems [137], 
[209], [210]. 
5.2 Development of a NMR pulse sequence to map intrinsically disordered 
protein (IDP)-heme interactions 
The developed new NMR approach is more sensitive and can help in discovering yet 
unknown heme-binding proteins along with the traditional NMR methods. NMR mapping 
applications have been used in pharmaceutical studies since 1976 [211] and witnessed the 
identification of a number of drugs and inhibitors [212]–[215]. The presented method can 
similarly be used for mapping of IDP-ligand interactions in pharmacological drug 
discoveries, e.g for small molecules in the fragment based drug discovery approaches where 
the interaction is too weak to be detected through biochemical or biophysical assays like 
ELISA and fluorescence resonance energy transfer (FRET) [216], [217]. 
5.3 The Interleukin-36 family cytokine interaction with heme 
A detailed study of IL-36α has been presented involving the determination of its NMR 
solution structure and its interaction via biophysical techniques like Raman, UV/Visible 
spectroscopy. However, further investigation of this interaction in in vivo and mouse 
studies could give more insight for its involvement in the diseases psoriasis and rheumatoid 
arthritis. 
Within this thesis a preliminary structure of IL-36β is presented. Although the final 
refined NMR solution structure of IL-36β has still to be calculated it already allowed to 
define the heme interaction sites and to compare the structural features with other 
members of this family. The interaction of heme with these cytokine class should be 
considered by the growing number of reports on IL-36 family members and their 
involvement in inflammation, rheumatoid arthritis, inflammation and latest involvement 
during pregnancy which could give further insight at biological level [165]. 
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5.4 Development of heme sensors 
There has been a number of reports in the last decade on development of heme sensors 
[218]–[221].During many pathological conditions like Malaria, sub arachnoid hemorrhage 
labile heme is accumulated in the body and exerts toxicity for the cells. It is important to 
characterize this labile heme for the therapeutic developments [218], [222]. This study 
would be beneficial to create heme sensors based upon the structural information obtained 
from how heme binds transiently to proteins or what is modulating the binding affinity. So 
it might contribute not only to determine the heme in pathological conditions but also to 
uncover the poorly understood nature of heme trafficking in organisms [219], [223]. 
5.5 Heme induced polyreactivity in antibodies 
Immunoglobulins are a new class of molecules which has been seen interacting with 
heme in the last few years [224]. Antibodies are the second most abundant molecules 
circulating in plasma after the albumin. It has been seen that heme can induce 
polyreactivity in immunoglobulins (IgG, IgM, IgE etc.) which resulted in new specific 
binding properties and thereby diversifies the antibodies functions [106], [225]. One study 
shows that heme induced polyreactivity helped in neutralization of Japanese Encephalitis 
viruses [226] while other indicates its potential in cancer therapeutics [227]. At the 
structural level very few information is available on how heme binds in the variable region 
of antibodies and induces polyreactivity. Knowledge obtained from the present study can 
be applied on designing a strategy to find the heme-binding motifs in antibodies and to 
elucidate the molecular dynamics changes of antibodies upon heme interaction. This could 
help in designing antibodies delivering drugs or could contribute to develop heme 
scavenging antibodies to prevent the deadly effect of heme on cells. 
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6 Conclusion 
We have validated the knowledge obtained from previous peptide-heme interaction 
studies at protein level. During this study we have shown the structural details upon heme 
interaction to intrinsically disordered proteins as well as structured globular proteins. 
Transient interaction of heme to the intrinsically disordered N-terminus of the CBS protein 
revealed the involvement of heme in the activity of this enzyme as well as possible 
conformational changes in structure upon heme interaction. It also emphasizes the 
probable role of these disordered regions in signaling. 
The study performed on interleukin-36 family members shows that among the family 
members different kinds of heme regulatory motifs (HRMs) are involved in heme binding 
with different affinity. We also shed the light at structural level on how N-terminal 
processing of pro-peptides in these cytokines leads to full activation. In vitro studies on 
these cytokines unravelled new types of HRMs for the first time with possible interaction 
through propionate groups of heme with side chains of residues in these HRMs. Thus, this 
study contributes more details to the growing classes of HRMs and adds some aspects for 
the determination of yet unknown transient heme-binding proteins. This study also adds 
with the IL-36 proteins three new structured proteins and with CBS1-40 an intrinsically 
disordered protein to the growing number of transiently heme-interacting proteins. 
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